attention the work of Dr. Denise L Faustman, see faustmanlab.org and pubmed.org faustman dl and the below. Please help see that BCG falls from the sky to all those who need same. It is safe, effective and inexpensive for those who suffer from autoimmune diseases. (Lawyer are not safe, cheap and effective).
Help do something for the healthcare system and commerce.
Neurology. 2013 Dec 4. [Epub ahead of print]
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS.
Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, Gasperini C, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M.
Abstract
OBJECTIVE:
To evaluate Bacille Calmette-Guérin (BCG) effects after clinically isolated syndromes (CIS).METHODS:
In a double-blind, placebo-controlled trial, participants were randomly assigned to receive BCG or placebo and monitored monthly with brain MRI (6 scans). Both groups then entered a preplanned phase with IM interferon-β-1a for 12 months. From month 18 onward, the patients took the disease-modifying therapies (DMTs) that their neurologist considered indicated in an open-label extension phase lasting up to 60 months.RESULTS:
Of 82 randomized subjects, 73 completed the study (33 vaccinated and 40 placebo). During the initial 6 months, the number of cumulative lesions was significantly lower in vaccinated people. The relative risks were 0.541 (95% confidence interval [CI] 0.308-0.956; p = 0.03) for gadolinium-enhancing lesions (the primary endpoint), 0.364 (95% CI 0.207-0.639; p = 0.001) for new and enlarging T2-hyperintense lesions, and 0.149 (95% CI 0.046-0.416; p = 0.001) for new T1-hypointense lesions. The number of total T1-hypointense lesions was lower in the BCG group at months 6, 12, and 18: mean changes from baseline were -0.09 ± 0.72 vs 0.75 ± 1.81 (p = 0.01), 0.0 ± 0.83 vs 0.88 ± 2.21 (p = 0.08), and -0.21 ± 1.03 vs 1.00 ± 2.49 (p = 0.02). After 60 months, the cumulative probability of clinically definite multiple sclerosis was lower in the BCG + DMT arm (hazard ratio = 0.52, 95% CI 0.27-0.99; p < 0.05), and more vaccinated people remained DMT-free (odds ratio = 0.20, 95% CI 0.04-0.93; p = 0.04).CONCLUSIONS:
Early BCG may benefit CIS and affect its long-term course.CLASSIFICATION OF EVIDENCE:
BCG, as compared to placebo, was associated with significantly reduced development of gadolinium-enhancing lesions in people with CIS for a 6-month period before starting immunomodulating therapy (Class I evidence).- PMID:
- 24306002
- [PubMed - as supplied by publisher]
Neurology. 1999 Oct 22;53(7):1588-9.
Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.
Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, Salvetti M.
Abstract
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Comment in
- Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. [Neurology. 2000]
- PMID:
- 10534275
- [PubMed - indexed for MEDLINE]
Lawsuit: Republic Airport workers damaged plane during blizzard
Photo credit: Handout | This photo courtesy of FlyforMS.org
shows a twin-engine plane that was allegedly damaged at Republic Airport
during the 2010 blizzard. The operator of the plane used mostly to
transport multiple sclerosis patients to treatment has sued two
companies that operate Republic Airport, claiming the Cessna 340 was
damaged after airport employees tried to tow it out of a snowdrift.
Holiday Blizzard 2010
Reader photos of the 2010 blizzard
Blizzard history: 122 years of snow on LI, NYC
Cezar Andrei Floroiu, the sole shareholder of Exigo -- a Manhattan-based company that owns the plane -- sued Farmingdale-based Flightways of Long Island Inc. and URS Corp., headquartered in San Francisco, for negligence.
The companies' workers tore the plane's tie-down hook and part of its tail section on Dec. 27, 2010, after trying to tow it from snow, according to the suit filed Dec. 23 in the Supreme Court of the State of New York.
Attempts to reach representatives from both companies were unsuccessful.
"It's like pulling a car from the bumper," said Floroiu, the pilot, adding that no patients were on the flight. "You know you're just going to take off the bumper."
The defendants acted in a "negligent manner" when they used a tow method that is prohibited by the Cessna 340 operating handbook, and without attempting easier and safer options, according to the suit.
Following a blizzard that brought 10 to 20 inches to parts of Long Island, the plane became stuck shortly after 6 p.m. upon exiting the runway onto the taxiway.
URS Corp. personnel advised Floroiu and his passengers to remain in the plane, while both companies tried to free the Cessna, according to the suit.
Floroiu and approximately three others waited in the cold and the dark for four hours, since the aircraft's battery had been drained, according to the suit. After witnessing the tow attempt, Floroiu exited the plane and directed a passenger to remove snow from one of the tires with a shovel. The passengers and workers then pushed the aircraft out of the snowdrift by hand, the suit said.
The suit seeks unspecified damages that Floroiu's attorney Benjamin Klein, of Manhattan-based The Klein Firm LLC, said would be a "five-figure number."
"There was just no willingness on the part of either defendant to compensate my client on the damages," Klein said. "They just sort of pointed the finger at one another."
The plane's damage rendered it unusable for more than two months, said Floroiu, causing him to lose momentum with Fly for MS -- an organization Floroiu founded in 2010 that flew to 31 countries to offer sightseeing flights to those affected by multiple sclerosis, raise funds and transport specialists and patients without access to care to hospitals for treatment."I got close to MS while investing in biotech companies that were developing [drugs] for MS," said Floroiu, a former Wall Street investor. "I was pretty impressed by the people who live with MS. It's such a terrible disease and they live with no cure. So, I thought I could do something about it."
No comments:
Post a Comment